US President Donald Trump has signed an executive order designed to expedite access to medical research and treatments involving psychedelic substances. The directive instructs the US Food and Drug Administration (FDA) to accelerate the evaluation process for drugs such as ibogaine, which some veteran groups believe could help treat post-traumatic stress disorder (PTSD).
During a signing ceremony held in the Oval Office, officials highlighted that these measures might lead to the reclassification of such drugs if clinical trials demonstrate their safety and effectiveness. In a significant development, Trump also announced a $50 million allocation of federal funds to support research on ibogaine.
The event was attended by military veterans, including Marcus Luttrell and Congressman Morgan Luttrell, as well as media personality Joe Rogan. Trump acknowledged that his awareness of ibogaine was partly influenced by discussions on Rogan’s show, where the topic had been featured prominently.
Officials emphasized the growing body of scientific evidence suggesting ibogaine’s potential benefits for mental health treatment. Trump remarked that although the drug was once considered taboo, it is now attracting broader attention and interest.
